Neumora Therapeutics Inc (NASDAQ: NMRA): The Stock We Should Bet On For Economic Growth In The Months To Come

In the last trading session, 1.54 million shares of the Neumora Therapeutics Inc (NASDAQ:NMRA) were traded, and its beta was 2.50. Most recently the company’s share price was $1.41, and it changed around $0.01 or 0.36% from the last close, which brings the market valuation of the company to $227.80M. NMRA currently trades at a discount to its 52-week high of $21.00, offering almost -1389.36% off that amount. The share price’s 52-week low was $1.40, which indicates that the current value has risen by an impressive 0.71% since then.

Neumora Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.44. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended NMRA as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Neumora Therapeutics Inc is expected to report earnings per share of -0.39 for the current quarter.

Neumora Therapeutics Inc (NASDAQ:NMRA) trade information

Instantly NMRA has showed a green trend with a performance of 0.36% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.7100 on recent trading dayincreased the stock’s daily price by 17.54%. The company’s shares are currently down -86.70% year-to-date, but still down -15.06% over the last five days. On the other hand, Neumora Therapeutics Inc (NASDAQ:NMRA) is -26.94% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 64.75% from its current value. Analyst projections state that NMRA is forecast to be at a low of $4 and a high of $4.

Forecasts for the next quarter put sales growth at 0.00%.

Neumora Therapeutics Inc earnings are expected to increase by 1.31% in 2025, but the outlook is negative -0.25% per year for the next five years.

NMRA Dividends

Neumora Therapeutics Inc’s next quarterly earnings report is expected to be released in April.

T. ROWE PRICE INVESTMENT MANAGEMENT, INC., with 3.2086% or 5.1 million shares worth $50.14 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 2.39 shares worth $3.37 million, making up 1.48% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 2.27 shares worth around $3.2 million, which represents about 1.41% of the total shares outstanding.